SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 64 figures, this 150-page report Asia Pacific Digital Health and Wellness Market 2023-2033 by Product ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 88 tables and 97 figures, this 206-page report Global Digital Health and Wellness Market 2023-2033 by Product (Hardware, ...

Major employers and innovators recognised at ceremony showcasing Ireland’s pharmaceutical leadership, as sector marks record ...

1 Day RANI 5.67% DJIA 0.30% Russell 2K -0.61% Health Care/Life Sciences -1.75% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […] Tenaya Therapeutics announced that it priced an underwritten, upsized initial public offering of ...

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been given an average rating of “Buy” by the seven brokerages that are covering the stock, Marketbeat.com reports.